成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 33332-25-1 Chemical Structure| 33332-25-1
Chemical Structure| 33332-25-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 33332-25-1

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Citations      Show More

Yuan, Gengyang ; Dhaynaut, Maeva ; Lan, Yu ; Guehl, Nicolas J. ; Huynh, Dalena ; Iyengar, Suhasini M. , et al.

Abstract: Metabotropic glutamate receptor 2 (mGluR2) is a therapeutic target for several neuropsychiatric disorders. An mGluR2 function in etiology could be unveiled by positron emission tomography (PET). In this regard, 5-(2-fluoro-4-[11C]methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide ([11C]13, [11C]mG2N001), a potent negative allosteric modulator (NAM), was developed to support this endeavor. [11C]13 was synthesized via the O-[11C]methylation of phenol 24 with a high molar activity of 212 ± 76 GBq/μmol (n = 5) and excellent radiochemical purity (>99%). PET imaging of [11C]13 in rats demonstrated its superior brain heterogeneity and reduced accumulation with pretreatment of mGluR2 NAMs, VU6001966 (9) and MNI-137 (26), the extent of which revealed a time-dependent drug effect of the blocking agents. In a nonhuman primate, [11C]13 selectively accumulated in mGluR2-rich regions and resulted in high-contrast brain images. Therefore, [11C]13 is a potential candidate for translational PET imaging of the mGluR2 function.

Hegde, Pooja V. ; Aragaw, Wassihun W. ; Cole, Malcolm S. ; Jachak, Gorakhnath ; Ragunathan, Priya ; Sharma, Sachin , et al.

Abstract: Tuberculosis (TB) remains a leading cause of infectious disease-related mortality and morbidity. Pyrazinamide (PZA) is a critical component of the first-line TB treatment regimen because of its sterilizing activity against non-replicating Mycobacterium tuberculosis (Mtb), but its mechanism of action has remained enigmatic. PZA is a prodrug converted by pyrazinamidase encoded by pncA within Mtb to the active moiety, pyrazinoic acid (POA) and PZA resistance is caused by loss-of-function mutations to pyrazinamidase. We have recently shown that POA induces targeted protein degradation of the enzyme PanD, a crucial component of the CoA biosynthetic pathway essential in Mtb. Based on the newly identified mechanism of action of POA, along with the crystal structure of PanD bound to POA, we designed several POA analogs using structure for interpretation to improve potency and overcome PZA resistance. We prepared and tested ring and carboxylic acid bioisosteres as well as 3, 5, 6 substitutions on the ring to study the structure activity relationships of the POA scaffold. All the analogs were evaluated for their whole cell antimycobacterial activity, and a few representative mols. were evaluated for their binding affinity, towards PanD, through isothermal titration calorimetry. We report that analogs with ring and carboxylic acid bioisosteres did not significantly enhance the antimicrobial activity, whereas the alkylamino-group substitutions at the 3 and 5 position of POA were found to be up to 5 to 10-fold more potent than POA. Further development and mechanistic anal. of these analogs may lead to a next generation POA analog for treating TB.

Keywords: Tuberculosis ; Pyrazinoic acid ; pyrazinamide

Alternative Products

Product Details of [ 33332-25-1 ]

CAS No. :33332-25-1
Formula : C6H5ClN2O2
M.W : 172.57
SMILES Code : ClC1=CN=C(C=N1)C(=O)OC
MDL No. :MFCD01632102
InChI Key :CVVMLRFXZPKILB-UHFFFAOYSA-N
Pubchem ID :406081

Safety of [ 33332-25-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Calculated chemistry of [ 33332-25-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.17
Num. rotatable bonds 2
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 38.32
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

52.08 ?2

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.5
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.47
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.92
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.26
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.38
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.8

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.48
Solubility 5.75 mg/ml ; 0.0333 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.13
Solubility 12.7 mg/ml ; 0.0737 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.34
Solubility 0.789 mg/ml ; 0.00457 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

 High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

 Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

 No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

 No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

 No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

 No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

 No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

 No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.02 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

 0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

 None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

 0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

 0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

 1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

 No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

 1.99

Application In Synthesis of [ 33332-25-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 33332-25-1 ]

[ 33332-25-1 ] Synthesis Path-Downstream   1~4

  • 1
  • [ 33332-25-1 ]
  • [ 848952-83-0 ]
YieldReaction ConditionsOperation in experiment
50% With hydrazine; In methanol; for 48.0h;Heating / reflux; Preparation 1; 5-ChloroDvrazine-2-carboxvlic acid hvdrazide; delta-chloropyrazine^-carboxylic acid methyl ester (10.02g, 58.25mmol) and hydrazine monohydrate (12.5ml_, 250mmol) were dissolved in methanol (40OmL) and the reaction mixture heated to reflux for 48 hours. The reaction mixture was then filtered and the precipitate collected dried in vacuo to yield the title product, 5.01 g (50%). 1H NMR(CDCI3, 400MHz) delta: 4.09(d, 2H), 8.52(s, 1 H), 8.66(bs, 1 H), 9.14(s, 1 H). Microanalysis: C5H5CIN4O requires: C 34.80; H 2.92; N 32.47; found C 34.89; H 2.91 , N 32.32. MS APCI+ m/z 173 [MH]+
50% With hydrazine; In methanol; for 48.0h;Heating / reflux; delta-chloro-pyrazine^-carboxylic acid methyl ester (10.02g, 58.25mmol) and hydrazine monohydrate(12.5mL, 250mmol) were dissolved in methanol (40OmL) and the reaction mixture heated to reflux for 48 hours. The reaction mixture was then filtered and the precipitate collected dried in vacuo to yield the title compound, 5.01 g (50%).1H NMR(CDCI3, 400MHz) delta: 4.09(d, 2H), 8.52(s, 1 H), 8.66(bs, 1 H), 9.14(s, 1 H). Microanalysis:C5H5CIN4O requires: C 34.80; H" 2.92; N 32.47; found C 34.89; H 2.91 , N 32.32. MS APCI+ m/z 173[MH]+
  • 2
  • [ 1196473-37-6 ]
  • [ 33332-25-1 ]
  • [ 1196473-63-8 ]
YieldReaction ConditionsOperation in experiment
5% With caesium carbonate; In N,N-dimethyl-formamide; at 20 - 90℃; To a solution of <strong>[1196473-37-6]3H-benzo[c][1,2]oxaborole-1,6-diol</strong> (0.37 g, 2.47 mmol) in anhydrous DMF (8 mL) were added Cs2CO3 (2.01 g, 2.71 mmol) and 5-chloro-pyrazine-2-carboxylic acid methyl ester (0.468 g, 2.71 mmol) at room temperature. After stirring at 90° C. for 1.5 h, the reaction mixture was cooled to 0° C., diluted with water (10 mL) and acidified to pH 3 using diluted hydrochloric acid. The off-white precipitate was collected, washed with water and dried to give the crude product which was purified by chromatography on silica gel (DCM/MeOH=40:3) to give 0.470 g (66.5percent yield) of product. MS (ESI) m/z=287 [M+H]+.
With caesium carbonate; In N,N-dimethyl-formamide; at 90℃; for 1.5h; To a solution of 20 (0.37 g, 2.47 mmol) in anhydrous DMF (8 mL) were added Cs2CO3 (2.01 g, 2.71 mmol) and 5-chloro-pyrazine-2-carboxylic acid methyl ester (0.468 g, 2.71 mmol) at room temperature. After stirring at 90 °C for 1.5 h, the reaction mixture was cooled to 0 °C, diluted with water (10 mL) and acidified to pH 3 using diluted hydrochloric acid. The off-white precipitate was collected, washed with water and dried to give the crude product which was purified by chromatography on silica gel (DCM/MeOH = 40:3) to give 0.47 g (66.5percent) of 21.
  • 3
  • [ 33332-25-1 ]
  • [ 1209646-17-2 ]
 

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 33332-25-1 ]

Chlorides

Chemical Structure| 23611-75-8

A134965 [23611-75-8]

Methyl 6-chloropyrazine-2-carboxylate

Similarity: 1.00

Chemical Structure| 1166831-45-3

A243080 [1166831-45-3]

Methyl 6-chloro-3-methylpyrazine-2-carboxylate

Similarity: 0.95

Chemical Structure| 23688-89-3

A133165 [23688-89-3]

6-Chloropyrazine-2-carboxylic acid

Similarity: 0.89

Chemical Structure| 36070-80-1

A184178 [36070-80-1]

5-Chloropyrazine-2-carboxylic acid

Similarity: 0.89

Chemical Structure| 76537-42-3

A190360 [76537-42-3]

5,6-Dichloropyrazine-2-carboxylic acid

Similarity: 0.86

Esters

Chemical Structure| 23611-75-8

A134965 [23611-75-8]

Methyl 6-chloropyrazine-2-carboxylate

Similarity: 1.00

Chemical Structure| 1166831-45-3

A243080 [1166831-45-3]

Methyl 6-chloro-3-methylpyrazine-2-carboxylate

Similarity: 0.95

Chemical Structure| 144692-85-3

A142077 [144692-85-3]

2,3-Dichlorofuro[3,4-b]pyrazine-5,7-dione

Similarity: 0.86

Chemical Structure| 1458-03-3

A207024 [1458-03-3]

Methyl 3-amino-6-chloropyrazine-2-carboxylate

Similarity: 0.85

Chemical Structure| 1458-18-0

A108171 [1458-18-0]

Methyl 3-amino-5,6-dichloropyrazine-2-carboxylate

Similarity: 0.82

Related Parent Nucleus of
[ 33332-25-1 ]

Pyrazines

Chemical Structure| 23611-75-8

A134965 [23611-75-8]

Methyl 6-chloropyrazine-2-carboxylate

Similarity: 1.00

Chemical Structure| 1166831-45-3

A243080 [1166831-45-3]

Methyl 6-chloro-3-methylpyrazine-2-carboxylate

Similarity: 0.95

Chemical Structure| 23688-89-3

A133165 [23688-89-3]

6-Chloropyrazine-2-carboxylic acid

Similarity: 0.89

Chemical Structure| 36070-80-1

A184178 [36070-80-1]

5-Chloropyrazine-2-carboxylic acid

Similarity: 0.89

Chemical Structure| 76537-42-3

A190360 [76537-42-3]

5,6-Dichloropyrazine-2-carboxylic acid

Similarity: 0.86